Table 3.
Success, relapse, and death rates for dogs in the cytosine arabinoside and non-cytosine arabinoside treatment groups.
| CA+ | CA– | p-value | |
|---|---|---|---|
| 1 month | |||
| Success | 19/21 (90%) | 27/30 (90%) | 0.95 |
| Relapse | 0/21 (0%) | 3/30 (10%) | 0.26 |
| Death | 2/21 (10%) | 0/30 (0%) | 0.16 |
| 3 months | |||
| Success | 16/21 (76%) | 22/30 (73%) | 0.82 |
| Relapse | 3/21 (14%) | 8/30 (27%) | 0.29 |
| Death | 2/21 (10%) | 0/30 (0%) | 0.16 |
| 6 months | |||
| Success | 15/21 (71%) | 18/30 (60%) | 0.40 |
| Relapse | 4/21 (19%) | 10/30 (33%) | 0.26 |
| Death | 2/21 (10%) | 2/30 (7%) | 1 |
| 9 months | |||
| Success | 15/21 (71%) | 14/30 (47%) | 0.08 |
| Relapse | 4/21 (19%) | 11/30 (37%) | 0.23 |
| Death | 2/21 (10%) | 5/30 (16%) | 0.68 |
| 12 months | |||
| Success | 15/21 (71%) | 10/30 (33%) | 0.007 |
| Relapse | 4/21 (19%) | 14/30 (47%) | 0.04 |
| Death | 2/21 (10%) | 6/30 (20%) | 0.44 |
| 18 months | |||
| Success | 13/21 (62%) | 10/30 (33%) | 0.04 |
| Relapse | 5/21 (24%) | 14/30 (47%) | 0.10 |
| Death | 3/21 (14%) | 6/30 (20%) | 0.72 |
| 36 months | |||
| Success | 12/21 (57%) | 9/30 (30%) | 0.05 |
| Relapse | 6/21 (29%) | 15/30 (50%) | 0.13 |
| Death | 3/21 (14%) | 6/30 (20%) | 0.72 |
CA+, cytosine arabinoside treatment group; CA–, non-cytosine arabinoside treatment group.
Bonferroni correction was applied to account for multiple independent analysis. Results were considered statistically significant for a p-value of < 0.0024.